Sat.Mar 09, 2024 - Fri.Mar 15, 2024

article thumbnail

Study: Gilead antiviral drug shows promise as a treatment for Ebola Sudan

STAT

A new study suggests the antiviral drug obeldesivir may be effective in curing Ebola Sudan infections, for which there are currently no approved vaccines or treatments. Scientists at the University of Texas Medical Branch in Galveston tested the drug, made by Gilead, in primates, starting treatment 24 hours after the animals were given what should have been a lethal dose of Sudan ebolavirus by intramuscular injection.

Vaccines 363
article thumbnail

After Amylyx drug failure, what’s next for ALS?

PharmaVoice

The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

299
299
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Madrigal wins FDA approval of first drug for MASH

BioPharma Dive

Rezdiffra’s clearance is a turning point in the fight against the liver disease. But its sales potential is unclear, and competition could emerge from popular weight loss drugs.

128
128
article thumbnail

When £17m isn’t enough: FTSE firms plead to pay bosses millions more

The Guardian - Pharmaceutical Industry

Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier There was a sharp intake of breath last month when the pharmaceuticals group AstraZeneca cemented chief executive Pascal Soriot’s position as the best-paid FTSE 100 boss with a £17m pay package , up from £15.3m a year earlier.

Packaging 128
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

STAT+: Medicare couldn’t cover Wegovy for weight loss. But now that it’s also a heart drug, the door is open

STAT

WASHINGTON — Novo Nordisk’s newly won permission to market the heart benefits of its obesity drug Wegovy could provide a backdoor way to expand access to the drug for people on Medicare, experts told STAT. Currently, Medicare is prohibited by law from covering medications for obesity treatment alone. While companies that manufacture wildly popular anti-obesity medications and their allies haven’t been successful in lobbying Congress to change the law , the Food and Drug

Labelling 363
article thumbnail

As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients

PharmaVoice

As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.

244
244

More Trending

article thumbnail

Why gut bacteria is the next frontier in medicine

pharmaphorum

Discover why gut bacteria are considered the next frontier in medicine in this informative article. Learn about the importance of the microbiome, its impact on health, and how it relates to conditions like Clostridiales difficile.

126
126
article thumbnail

Opinion: No parent who has seen the children I’ve treated for measles would refuse a vaccine

STAT

Over the past year, I have watched many children die of measles. In the final stages, little lungs, filled with fluid and racked with inflammation, struggle for oxygen. The victims breathe faster and faster, gasping for air until, exhausted, they stop.

Vaccines 364
article thumbnail

These biotech hotspots are ripe for IPOs

PharmaVoice

Biotech IPOs are off to the races in 2024, and investors are betting on horses that are derisked in targeted areas.

173
173
article thumbnail

Mahendra Patel: 'Let’s have the difficult conversations'

The Pharmacist

Working together with other healthcare professions will be crucial to embedding community pharmacy within the future of the NHS, pharmacist and academic Dr Mahendra Patel has told The Pharmacist. And the new cross-sector Independent Pharmacy Professional Leadership Advisory Board is an opportunity for community pharmacy to have an ‘equal voice’ in ‘difficult conversations’ that set […] The post Mahendra Patel: 'Let’s have the difficult conversations' appeared first on The Pharmac

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Navigating digital transformation in pharma: The rise of mobile messaging

pharmaphorum

Popular mobile messaging apps that offer end-to-end encryption for their users' communications means that the content of messages is only accessible to the sender and the recipient. However, like any software, they still have potential cybersecurity risks and compliance concerns that users should be aware of - especially in pharma.

article thumbnail

Rigid rules at methadone clinics are jeopardizing patients’ path to recovery from opioid addiction

STAT

DETROIT — Every morning, Rebecca Smith, nursing a surgically repaired knee, carefully walks down the hallway of her brutalist brick apartment building, takes the elevator one floor to the lobby, and negotiates the sharply angled driveway outside. There, she waits for an Uber to take her to the last place she wants to go: her methadone clinic.

363
363
article thumbnail

Madrigal, FDA approval in hand, outlines plan to sell MASH drug

BioPharma Dive

The company expects initial uptake of Rezdiffra, which costs $47,400 per year, to be slow as doctors and insurers establish the protocols needed to find patients eligible for treatment.

122
122
article thumbnail

Pain is reduced by almost half with cannabis-based medicines – report finds

Outsourcing Pharma

On March 7, Celadon Pharmaceuticals plc, a leading UK-based pharmaceutical company specializing in cannabis-based medicines, unveiled promising findings from an early economic analysis of its chronic pain clinical trial, dubbed CANPAIN.

article thumbnail

Transitioning PROs from paper to digital: Maintaining data integrity and patient experience

pharmaphorum

Transitioning patient-reported outcomes (PROs) from paper to digital (ePRO) is crucial for maintaining data integrity and improving the patient experience. Learn how to seamlessly make this transition and optimise your data collection process.

122
122
article thumbnail

STAT+: Hemophilia gene therapies arrived after 40 years of struggle. Where are the patients?

STAT

As a boy growing up with hemophilia A, Noah Frederick reserved the end of his annual checkups to talk about new technologies. His doctor walked through various experimental approaches for the bleeding disorder and, invariably, gene therapy. It was coming, he always said, in your lifetime. Last year, it finally arrived. But Frederick, now a 23-year-old software engineer, isn’t sure he’ll get it.

360
360
article thumbnail

After surprise trial failure, ALS doctors brace for one less treatment option

BioPharma Dive

Physicians are preparing for tough conversations with patients on Amylyx Pharmaceuticals’ drug, Relyvrio, while holding out hope it still may help some with the disease.

122
122
article thumbnail

Swedish researchers develop new AI computer model to detect lymphatic cancer

Pharma Times

In the study, the Lymphoma Artificial Reader System accurately detected 90% of lymphatic cancers

151
151
article thumbnail

Lilly’s Alzheimer’s drug delayed as FDA seeks adcomm

pharmaphorum

The FDA has said it will seek the advice of independent advisors before it concludes its review of Eli Lilly’s amyloid-targeting Alzheimer’s disease therapy donanemab, delaying its review of the drug. Lilly said the US regulator “wants to further understand topics related to evaluating the safety and efficacy of donanemab,” which includes the safety and efficacy results of its pivotal TRAILBLAZER-ALZ 2 study.

124
124
article thumbnail

STAT+: Small studies offer hope CAR-T can fight an aggressive brain cancer

STAT

A series of new studies are raising hopes that CAR-T , a process in which treatments are made by genetically editing a patient’s own white blood cells, can eventually be used to treat an incurable and deadly type of brain cancer, called glioblastoma multiforme, or GBM. In the most dramatic result, from a three-person study conducted by researchers at Massachusetts General Hospital, a 72-year-old man saw his tumor shrink 18.5% in just two days and then decrease further over the next two mo

Hospitals 358
article thumbnail

German biotech Tubulis cashes in on ADC ‘momentum’ with €128M financing

BioPharma Dive

The funding for the startup, which partnered with Bristol Myers Squibb last year, adds to a surge of recent investments in developers of antibody-drug conjugates.

123
123
article thumbnail

What’s next for AAV gene therapies in 2024?

Pharmaceutical Technology

Upcoming regulatory events for pipeline AAV gene therapies, with a focus on neuromuscular and blood disorders, are setting high expectations for the space in 2024.

119
119
article thumbnail

Changing Faces: Agency, consultancy, and investor hires from February 2024

pharmaphorum

Discover the latest agency, consultancy, and investor hires from February 2024, including personnel from OVID Health, Avalere, WE Communications, and Eurozeo. Stay updated with industry movements and key players.

article thumbnail

STAT+: UnitedHealth is on a buying spree of outpatient surgery centers

STAT

UnitedHealth Group quietly acquired dozens of outpatient facilities in 2023, with a particular focus on surgery centers, according to a STAT review of company financial filings. Those acquisitions — nearly all of which the company never announced — build on the network of some 90,000 physicians UnitedHealth Group has amassed in recent years.

363
363
article thumbnail

Amylyx CEOs look for a path forward following major setback

BioPharma Dive

Justin Klee and Joshua Cohen spoke to BioPharma Dive about the next steps for their company, which is considering pulling its only product from market after the drug failed a confirmatory study in ALS.

117
117
article thumbnail

Biomarkers becoming important for approval of ALS therapies: GlobalData

Express Pharma

Understanding the integrated stress response is an important next step towards grasping the importance of target engagement biomarkers within ALS The recently concluded AD/PD 2024 International Conference on Alzheimer’s Disease (AD) and Parkinson’s Disease (PD) focused on innovative approaches poised to revolutionise the treatment of amyotrophic lateral sclerosis (ALS) and the use of neurochemical biomarkers in ALS drug development.

article thumbnail

Changing Faces: Digital and supplier hires from February 2024

pharmaphorum

Explore the latest digital and supplier hires in the pharmaceutical industry, including Campbell, EMS Healthcare, PhRMA, and Exscientia in February 2024. Stay updated on the changing faces in industry.

115
115
article thumbnail

Opinion: Disabled scientists are often left out of academia. The NIH can help change that

STAT

Despite being the largest minority in the nation , disabled people like us have been structurally and institutionally obstructed from entering research-dominated fields. When they do manage to break through, they are seldom given the support and accommodations needed to sustain employment and thrive in their professional lives. As we have experienced, including people with disabilities in academic leadership and decision-making positions can lead to innovation, creative problem-solving, and insi

363
363
article thumbnail

BIO changes stance, backs bill to limit China’s role in US biotech

BioPharma Dive

Pressed by lawmakers, the lobbying group is also “taking steps” to end its relationship with Wuxi-AppTec, a major contract manufacturer to the biopharmaceutical industry.

114
114
article thumbnail

Uniform Code for Pharmaceutical Marketing Practices 2024 rolled out

Express Pharma

The Government has rolled out the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024. This initiative, spearheaded by the Ministry of Chemicals and Fertilizers, seeks to curb misleading promotional activities and ensure responsible marketing practices within the sector. Some key features of UCPMP 2024 are: Ethical promotion: The UCPMP mandates that drug promotion must adhere to stringent ethical criteria.

Hospitals 111
article thumbnail

Avoiding the data swamp: The transformative power of AI

pharmaphorum

In the latest episode of the pharmaphorum podcast, host Nicole Raleigh speaks (virtually) with Nathan Clark, founder and CEO of Ganymede, a modern data platform and Cloud infrastructure for science, to discuss the evolving role of the Cloud in biopharma and some rather revolutionary tools in AI drug discovery.

115
115
article thumbnail

What the brains of song birds can teach us about human stuttering

STAT

A symphony of synapses fires every time a songbird sings. For Erich Jarvis, a neurobiologist at Rockefeller University, the neural pathways he finds particularly interesting inside a birds’ brain are those that enable the bird to make new sounds from listening to their environment. This is an ability known as vocal learning, and is perhaps most notably exhibited when a parrot mimics a person’s speech (or profanity).

348
348
article thumbnail

Older Adults’ Experience with Opioid Use, Deprescribing

Pharmaceutical Commerce

A qualitative study explores how these drugs are impacting these patients’ lives, while digging deeper into the possibility of deprescribing, with insight from primary care physicians.

111
111
article thumbnail

Pharma Industry Townhall to be held in Mumbai

Express Pharma

The upcoming Pharma Industry Townhall by PharmaState Academy offers an array of insightful talks, panel discussions, and presentations. The details are as follows: Event Date: March 16, 2024 Location: Radisson Blu Marol Andheri Time: 09:00 AM – 05:00 PM The event aims to equip professionals with the latest knowledge and strategies crucial for navigating the industry’s changing dynamics.

article thumbnail

Amylyx plummets as confirmatory trial of ALS drug fails

pharmaphorum

Shares in Amylyx have cratered after the company reported a confirmatory trial of its amyotrophic lateral sclerosis (ALS) therapy Relyvrio missed all its objectives, putting its accelerated approval in jeopardy.

115
115